Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics
Feb. 25, 2021—A new partnership between Vanderbilt University’s Warren Center for Neuroscience Drug Discovery and clinical stage biopharmaceutical company Soleno Therapeutics will further research into new clinical treatments for multiple obesity syndromes.
Feb. 17, 2021—Vanderbilt biochemist Yi Ren is part of a team that has identified a new behavior of a SARS-CoV-2 protein and discovered that interfering with its function can block virus replication in host cells. This opens up the potential for new therapeutic targets for COVID-19.
Feb. 12, 2021—Bruce Carter, professor of biochemistry and an associate director of the Vanderbilt Brain Institute, has been appointed to the scientific advisory board of the CMT Research Foundation, which shapes research directions and therapeutic development of Charcot-Marie-Tooth disease.
Feb. 9, 2021—Biomedical researchers across Vanderbilt University will convene to discuss the history and impact of Black biomedical scientists on Monday, Feb. 15, at noon CT.
Cortez named interim chair in the Department of Biochemistry; York named Impossible Foods chief science officer
Dec. 8, 2020—David Cortez, Richard N. Armstrong Chair for Innovation in Biochemistry and professor of biochemistry, has been named interim chair in the Department of Biochemistry beginning Jan. 1. This follows the departure of John York, who was recently named chief science officer of California-based food technology startup Impossible Foods.
Nov. 24, 2020—Read about the latest faculty, staff and student awards, appointments and achievements.
Nov. 17, 2020—Further research by biochemistry professors Charles Sanders and Bruce Carter into therapeutics for Charcot-Marie-Tooth disease, an inherited condition that damages peripheral nerves, will be funded by Ancora Innovation LLC, a Deerfield Management company that supports Vanderbilt’s innovative life science research.
Nov. 17, 2020—Vanderbilt biochemists figure out how the little-understood Envelope protein helps SARS-CoV-2 function and how to disrupt the endogenously creative virus.
Nov. 12, 2020—Vanderbilt contributes molecular imaging data of kidney to the Human BioMolecular Atlas Program, a consortium of 18 diverse collaborative research teams across the United States and Europe.
Nov. 9, 2020—Yi Ren, assistant professor of biochemistry, has contributed to research on the function and impact of the SARS-CoV-2 protein on immune signaling protein in host cells. This understanding may lead to the development of immune-enhancing therapeutics.
Nov. 6, 2020—Assistant Professor of Biochemistry Yi Ren and her team have made several discoveries to illuminate the mechanisms of key host-pathogen interactions involving viruses, with implications for gaining a better understanding of SARS-CoV-2, the virus that causes COVID-19.
Oct. 27, 2020—Vanderbilt researchers—including Charles Sanders, associate dean for research and professor of biochemistry, and graduate student Justin Marinko—have illuminated the cause of Charcot-Marie-Tooth disease, putting them on the road to developing therapeutic approaches for the disease that affects one in 2,500 people.